Table 5.

Subgroup analysis

	Physicians				Patients: psoriasis severity
	General practitioners	Non-GPs	Dermatologists only	Non-dermatologists	Mild patients only	Moderate and severe patients
	n =36	n  =125	n  = 93	n  = 68	n  = 153	n  = 145
Attribute	Coefficient ( P  >  z )	Coefficient ( P  >  z )	Coefficient ( P  >  z )	Coefficient ( P  >  z )	Coefficient ( P  >  z )	Coefficient ( P  >  z )
PASI 90 (per 10% increase)	0.2197 (0.000)	0.1599 (0.000)	0.1571 (0.000)	0.1909 (0.000)	0.1358 (0.000)	0.1366 (0.000)
Stop rate (per 5% increase)	− 0.0321 (0.136)	− 0.0378 (0.001)	− 0.0443 (0.001)	− 0.0269 (0.082)	− 0.0266 (0.013)	− 0.0310 (0.003)
Bio-holiday (Yes)	0.0087 (0.927)	0.1968 (0.000)	0.1719 (0.002)	0.1355 (0.043)	0.1630 (0.000)	0.1915 (0.000)
Risk AE (per 1% increase)	− 0.0579 (0.060)	− 0.1092 (0.000)	− 0.1120 (0.000)	− 0.0782 (0.000)	− 0.1328 (0.000)	− 0.0959 (0.000)
Injection frequency (5 additional)	− 0.0003 (0.993)	− 0.0540 (0.001)	− 0.0487 (0.012)	− 0.0390 (0.092)	− 0.1130 (0.000)	− 0.1025 (0.000)
Injection type (IV)	− 0.6554 (0.000)	− 0.4325 (0.000)	− 0.4659 (0.000)	− 0.4888 (0.000)	− 0.1243 (0.005)	− 0.0315 (0.477)
Injection—who (HCP at clinic)	0.4365 (0.000)	0.0141 (0.772)	− 0.0436 (0.442)	0.3006 (0.000)	0.5339 (0.000)	0.2982 (0.000)
Observations	1152	4000	2976	2176	4896	4640
Log likelihood	− 331.0619	− 1240.7173	− 921.5068	− 654.4368	− 1481.2026	− 1470.9213
Swait − Louviere LL Ratio Test Statistic	− 27.91		− 19.58		− 20.74
Results	Exceeds test statistic, so samples are deemed different		Exceeds test statistic, so samples are deemed different		Exceeds test statistic, so samples are deemed different

Bold values indicate statistical significance at the 0.05 level

AE adverse events, HCP healthcare provider, IV intravenous, PASI 90 90% reduction in the Psoriasis Area and Severity Index score